Poxel Expands Metabolic Pipeline Through Strategic Acquisition Agreement With DeuteRx For DRX-065, A Novel Clinical Stage Drug Candidate For NASH, And Other Programs

Press/Media

Period30 Aug 2018

Media coverage

1

Media coverage